Subsidies & Funding

We empower medical innovation

Project Management

We manage your EU Horizon 2020 project

Business Strategy

We support successful commercialisation

Funding database

EU & non EU subsidies

News

Which opportunity in the Innovative Medicines Initiative (IMI) is right for you?

March 10 2016

The Innovative Medicines Initiative (IMI) is the world's biggest public-private partnership (PPP) in the life sciences. Through the IMI 2 programme, it has a €3.3 billion budget for the period 2014-2024. Are you thinking about participating in an IMI project? Preparation is everything! The new calls for proposals are expected to be launched early April.

The aim of IMI is to improve health by speeding up the development of, and patient access to, innovative medicines. To submit a successful project, you will need to form a consortium consisting of key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. Then, apply for support in response to an open Call for proposals.

The following topics are under consideration for inclusion in Calls for proposals to be launched in 2016:

  • A European distributed data network (DDN) project to facilitate intra-EU access to, and analysis of, real world data to improve health outcomes for EU patients (link to PDF)
  • Addressing the clinical burden of Clostridium difficile infection (CDI): evaluation of the burden, current practices and set up of a European research platform (link to PDF)
  • Development of immune tolerance therapies for the treatment of rheumatic diseases (link to PDF)
  • Data quality in preclinical research and development (link to PDF)
  • Next generation of electronic translational safety – NEXGETS (link to PDF)
  • Development and validation of technology enabled, quantitative and sensitive measures of functional decline in people with early stage Alzheimer’s disease (RADAR-AD) (link to PDF)
  • Identification and validation of non-invasive markers across the spectrum of nonalcoholic fatty liver disease (NAFLD) (link to PDF)
  • Joint influenza vaccine effectiveness surveillance (JIVES)

At ttopstart we are specialised in forming complementary consortia consisting of key players in healthcare with a competitive edge. We serve leading researchers and innovative companies exclusively in the fields of life sciences, medical technology and health in more than 19 European countries and the US by acquiring funding for cutting-edge research and development. Are you thinking about submitting a proposal to IMI but not sure about your chances or which partners to include in your consortium? You are always free to contact us to discuss your possibilities.

All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be communicated after approval by the IMI Governing Board.

Share this
Contact

Karlijn Bastiaansen, PhD